An der Goldgrube 12
55131 Mainz, de
+49 (89) 990178-0
Fusion Antibodies and MAB Discovery to collaborate on the development of fully humanized antibodies
"We are very pleased to be working with Fusion Antibodies, a well-respected antibody engineering firm with strong expertise in humanization," said Dr. Stephan Fischer, Chief Executive Officer of MAB Discovery. "The planned collaboration will enable us to provide our customers added value by offering high-quality humanized antibodies that are ready to be validated and brought into development. We also expect that combining our technologies will reduce the time from target to clinical candidate."
"Through this collaboration we are able to create synergies and provide clients with perfect antibody candidates. They will get access to rapid discovery and development of new antibodies through MAB Discovery's unique immunization and B cell cloning technology. MAB Discovery has developed a rabbit-based platform that produces monoclonal antibodies with unprecedented epitope coverage and potency," said Dr. Paul Kerr, Managing Director at Fusion Antibodies.
About Fusion Antibodies
Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies, Antibody Engineering Projects and cell line development. With 15+ years of experience in the medical research & diagnostic industry, with >50 humanized projects to date (from Rabbit, Rat, Mouse, Chicken, Llama); Fusion Antibodies have extensive experience in accelerating therapeutic immunotherapy research towards the clinic.
Fusion Antibodies has the knowledge and expertise to build and deliver a modular package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx(TM) technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success. Visit their website at www.fusionantibodies.com to find out more.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.